Compritol® 888 LIPID matrix via twin screw extruder

Abishek Wadhwa, Vashish Mathura, Mahalaxmi Rathnanand, Anup Naha, Shaila Angela Lewis

Research output: Contribution to journalArticle

Abstract

Objective: The objective of this research was to explore the potential of Hot Melt Extrusion (HME) technique by using theophylline as the model drug to produce sustained release tablets utilizing Compritol®888 ATO as the retarding material and to study the influence of lipid: excipient ratio, excipient type as well as the processing conditions of the extruder on the release profile. Methods: The tablets prepared using hot fusion method was compared to the ones concocted by the HME technology. During the HME process, a powder mixture of moisture-free drug, lipid, and other adjuncts was introduced into the extruder and liquefied inside the barrel of the extruder. The in vitro dissolution studies of the formulations were carried out in pH 7.2 buffer using USP Apparatus 2. The extrudates were characterized via differential scanning calorimetry. Results: Comparing the two methods of processing, it was observed by the dissolution studies using phosphate buffer pH 7.2, that the tablets prepared by Hot Melt Extrusion method had a higher extent of release where all 3 formulations crossed 80% at the 8-hour mark, whereas the tablets prepared by hot fusion method did not show such consistency. Conclusion: This study demonstrated the fact that Compritol®888 ATO is a suitable waxy material that can be used as a matrix-forming agent to control the release of theophylline using the Hot Melt Extrusion process.

Original languageEnglish
Pages (from-to)261-264
Number of pages4
JournalInternational Journal of Applied Pharmaceutics
Volume11
Issue number1
DOIs
Publication statusPublished - 01-01-2019

Fingerprint

Tablets
Excipients
Theophylline
Buffers
Lipids
Differential Scanning Calorimetry
Pharmaceutical Preparations
Powders
Phosphates
glyceryl behenate
Technology
Research

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{9254d3a804184e608d23fe085cbc8cef,
title = "Compritol{\circledR} 888 LIPID matrix via twin screw extruder",
abstract = "Objective: The objective of this research was to explore the potential of Hot Melt Extrusion (HME) technique by using theophylline as the model drug to produce sustained release tablets utilizing Compritol{\circledR}888 ATO as the retarding material and to study the influence of lipid: excipient ratio, excipient type as well as the processing conditions of the extruder on the release profile. Methods: The tablets prepared using hot fusion method was compared to the ones concocted by the HME technology. During the HME process, a powder mixture of moisture-free drug, lipid, and other adjuncts was introduced into the extruder and liquefied inside the barrel of the extruder. The in vitro dissolution studies of the formulations were carried out in pH 7.2 buffer using USP Apparatus 2. The extrudates were characterized via differential scanning calorimetry. Results: Comparing the two methods of processing, it was observed by the dissolution studies using phosphate buffer pH 7.2, that the tablets prepared by Hot Melt Extrusion method had a higher extent of release where all 3 formulations crossed 80{\%} at the 8-hour mark, whereas the tablets prepared by hot fusion method did not show such consistency. Conclusion: This study demonstrated the fact that Compritol{\circledR}888 ATO is a suitable waxy material that can be used as a matrix-forming agent to control the release of theophylline using the Hot Melt Extrusion process.",
author = "Abishek Wadhwa and Vashish Mathura and Mahalaxmi Rathnanand and Anup Naha and Lewis, {Shaila Angela}",
year = "2019",
month = "1",
day = "1",
doi = "10.22159/ijap.2019v11i1.29675",
language = "English",
volume = "11",
pages = "261--264",
journal = "International Journal of Applied Pharmaceutics",
issn = "0975-7058",
publisher = "International Journal of Applied Pharmaceutics",
number = "1",

}

Compritol® 888 LIPID matrix via twin screw extruder. / Wadhwa, Abishek; Mathura, Vashish; Rathnanand, Mahalaxmi; Naha, Anup; Lewis, Shaila Angela.

In: International Journal of Applied Pharmaceutics, Vol. 11, No. 1, 01.01.2019, p. 261-264.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Compritol® 888 LIPID matrix via twin screw extruder

AU - Wadhwa, Abishek

AU - Mathura, Vashish

AU - Rathnanand, Mahalaxmi

AU - Naha, Anup

AU - Lewis, Shaila Angela

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: The objective of this research was to explore the potential of Hot Melt Extrusion (HME) technique by using theophylline as the model drug to produce sustained release tablets utilizing Compritol®888 ATO as the retarding material and to study the influence of lipid: excipient ratio, excipient type as well as the processing conditions of the extruder on the release profile. Methods: The tablets prepared using hot fusion method was compared to the ones concocted by the HME technology. During the HME process, a powder mixture of moisture-free drug, lipid, and other adjuncts was introduced into the extruder and liquefied inside the barrel of the extruder. The in vitro dissolution studies of the formulations were carried out in pH 7.2 buffer using USP Apparatus 2. The extrudates were characterized via differential scanning calorimetry. Results: Comparing the two methods of processing, it was observed by the dissolution studies using phosphate buffer pH 7.2, that the tablets prepared by Hot Melt Extrusion method had a higher extent of release where all 3 formulations crossed 80% at the 8-hour mark, whereas the tablets prepared by hot fusion method did not show such consistency. Conclusion: This study demonstrated the fact that Compritol®888 ATO is a suitable waxy material that can be used as a matrix-forming agent to control the release of theophylline using the Hot Melt Extrusion process.

AB - Objective: The objective of this research was to explore the potential of Hot Melt Extrusion (HME) technique by using theophylline as the model drug to produce sustained release tablets utilizing Compritol®888 ATO as the retarding material and to study the influence of lipid: excipient ratio, excipient type as well as the processing conditions of the extruder on the release profile. Methods: The tablets prepared using hot fusion method was compared to the ones concocted by the HME technology. During the HME process, a powder mixture of moisture-free drug, lipid, and other adjuncts was introduced into the extruder and liquefied inside the barrel of the extruder. The in vitro dissolution studies of the formulations were carried out in pH 7.2 buffer using USP Apparatus 2. The extrudates were characterized via differential scanning calorimetry. Results: Comparing the two methods of processing, it was observed by the dissolution studies using phosphate buffer pH 7.2, that the tablets prepared by Hot Melt Extrusion method had a higher extent of release where all 3 formulations crossed 80% at the 8-hour mark, whereas the tablets prepared by hot fusion method did not show such consistency. Conclusion: This study demonstrated the fact that Compritol®888 ATO is a suitable waxy material that can be used as a matrix-forming agent to control the release of theophylline using the Hot Melt Extrusion process.

UR - http://www.scopus.com/inward/record.url?scp=85067928912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067928912&partnerID=8YFLogxK

U2 - 10.22159/ijap.2019v11i1.29675

DO - 10.22159/ijap.2019v11i1.29675

M3 - Article

VL - 11

SP - 261

EP - 264

JO - International Journal of Applied Pharmaceutics

JF - International Journal of Applied Pharmaceutics

SN - 0975-7058

IS - 1

ER -